Cytokinetics, Incorporated (NASDAQ: CYTK) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -6.84 | Insider Own | 1.10% | Shs Outstand | 124.43M | Perf Week | -0.48% |
| Market Cap | 9.55B | Forward P/E | - | EPS next Y | -4.67 | Insider Trans | -29.41% | Shs Float | 119.24M | Perf Month | -10.82% |
| Enterprise Value | 10.57B | PEG | 0.32 | EPS next Q | - | Inst Own | - | Short Float | 14.30% | Perf Quarter | 3.32% |
| Income | -842.44M | P/S | 134.60 | EPS this Y | 7.60% | Inst Trans | - | Short Ratio | 6.61 | Perf Half Y | 27.42% |
| Sales | 70.96M | P/B | - | EPS next Y | 26.12% | ROA | -46.45% | Short Interest | 17.05M | Perf YTD | 20.81% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | 163.98% | 52W High | 88.53 -13.08% | Perf Year | 118.44% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -39.33% | 52W Low | 32.97 133.38% | Perf 3Y | 146.98% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -2.52% 9.46% | Gross Margin | 84.97% | Volatility | 4.27% 3.78% | Perf 5Y | 158.63% |
| Dividend TTM | - | EV/Sales | 148.91 | EPS Y/Y TTM | -30.04% | Oper. Margin | -992.98% | ATR (14) | 3.14 | Perf 10Y | 671.46% |
| Dividend Ex-Date | - | Quick Ratio | 6.66 | Sales Y/Y TTM | 488.89% | Profit Margin | -1259.87% | RSI (14) | 42.98 | Recom | 2.03 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.66 | EPS Q/Q | -22.79% | SMA20 | -4.08% | Beta | 0.32 | Target Price | 109.30 |
| Payout | 0.00% | Debt/Eq | - | Sales Q/Q | 850.00% | SMA50 | -2.44% | Rel Volume | 1.63 | Prev Close | 76.76 |
| Employees | 673 | LT Debt/Eq | -1.85 | Earnings | Oct 29 | SMA200 | 12.24% | Avg Volume | 2.21M | Price | 76.95 |
| IPO Date | Apr 26, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.07% 127.21% | Net Debt/EBITDA | -1.24 | Volume | 3,604,387 | Change | 0.25% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Needham | Buy | $102 → $112 |
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $117 → $112 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $119 → $117 |
| Jun-29-26 | Upgrade | UBS | Neutral → Buy | $119 → $115 |
| Jun-24-26 | Reiterated | Mizuho | Outperform | $99 → $118 |
| Jun-17-26 | Reiterated | RBC Capital | Outperform | $101 → $119 |
| May-11-26 | Reiterated | HC Wainwright & Co. | Buy | $136 → $140 |
| May-06-26 | Reiterated | UBS | Neutral | $101 → $119 |
| May-06-26 | Reiterated | Stifel Nicolaus | $98 → $108 | |
| May-06-26 | Reiterated | Morgan Stanley | Overweight | $90 → $103 |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 71 | 88 | 18 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11 | 10 | 339 | — | — | — | — | — | — | |
| Gross Profit | 60 | 78 | -321 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 370 | 284 | 215 | — | — | — | — | — | — | |
| Research and Development | 395 | 406 | 339 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -339 | — | — | — | — | — | — | |
| Operating Income | -705 | -612 | -536 | — | — | — | — | — | — | |
| Interest Expense | 89 | 104 | 87 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -99 | -69 | 33 | — | — | — | — | — | — | |
| Net Income Before Taxes | -894 | -785 | -590 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -894 | -785 | -590 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -894 | -785 | -590 | — | — | — | — | — | — | |
| Net Income | -894 | -785 | -590 | — | — | — | — | — | — | |
| EPS (Recurring) | -7.21 | -6.54 | -5.26 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -7.21 | -6.54 | -5.26 | — | — | — | — | — | — | |
| EPS (Diluted) | -7.22 | -6.54 | -5.26 | — | — | — | — | — | — | |
| EBITDA | -818 | -775 | -493 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 143.06 | 86.65 | 292.69 | — | — | — | — | — | — | |
| Gross Margin | 84.51 | 88.64 | -1,783.33 | — | — | — | — | — | — | |
| Operating Margin | -992.96 | -695.45 | -2,977.78 | — | — | — | — | — | — | |
| Net Margin | -1,259.15 | -892.05 | -3,277.78 | — | — | — | — | — | — | |
| Shares Outstanding | 132 | 120 | 112 | — | — | — | — | — | — | |
| Market Capitalization | 10,158 | 7,625 | 5,268 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer | Jul 30 '26 | Option Exercise | 23.26 | 14,000 | 325,640 | 72,555 | Jul 30 |
| Callos Andrew | EVP, Chief Commercial Officer | Jul 30 '26 | Sale | 79.88 | 14,000 | 1,118,320 | 58,555 | Jul 30 |
| Blum Robert I | President & CEO | Jul 27 '26 | Option Exercise | 10.60 | 7,500 | 79,500 | 385,320 | Jul 27 |
| Blum Robert I | President & CEO | Jul 27 '26 | Sale | 80.87 | 7,500 | 606,525 | 377,820 | Jul 27 |
| Malik Fady Ibraham | EVP Research & Development | Jul 21 '26 | Sale | 80.59 | 3,500 | 282,065 | 153,902 | Jul 23 |
| Malik Fady Ibraham | EVP Research & Development | Jul 21 '26 | Option Exercise | 7.80 | 3,500 | 27,300 | 157,402 | Jul 23 |
| Blum Robert I | President & CEO | Jul 13 '26 | Sale | 82.02 | 7,490 | 614,330 | 377,820 | Jul 14 |
| Blum Robert I | President & CEO | Jul 13 '26 | Option Exercise | 10.60 | 7,490 | 79,394 | 385,310 | Jul 14 |
| Malik Fady Ibraham | EVP Research & Development | Jul 07 '26 | Sale | 86.62 | 3,500 | 303,170 | 153,902 | Jul 07 |
| Malik Fady Ibraham | EVP Research & Development | Jul 07 '26 | Option Exercise | 7.80 | 3,500 | 27,300 | 157,402 | Jul 07 |
| Blum Robert I | President & CEO | Jul 01 '26 | Sale | 84.92 | 7,500 | 636,900 | 377,830 | Jul 02 |
| Callos Andrew | EVP, Chief Commercial Officer | Jul 01 '26 | Option Exercise | 23.26 | 15,000 | 348,900 | 73,555 | Jul 02 |
| Callos Andrew | EVP, Chief Commercial Officer | Jul 01 '26 | Sale | 85.80 | 15,000 | 1,287,000 | 58,555 | Jul 02 |
| Lee Sung | EVP, Chief Financial Officer | Jul 01 '26 | Option Exercise | 48.51 | 1,112 | 53,943 | 64,333 | Jul 02 |
| Lee Sung | EVP, Chief Financial Officer | Jul 01 '26 | Sale | 87.79 | 1,112 | 97,622 | 63,221 | Jul 02 |